Literature DB >> 22229268

CD73 protects kidney from ischemia-reperfusion injury through reduction of free radicals.

Rongrong Jian1, Yong Sun, Yingjian Wang, Jerry Yu, Lingling Zhong, Ping Zhou.   

Abstract

Renal ischemia-reperfusion injury (IRI) may cause severe systemic diseases. Extracellular adenosine is anti-inflammatory especially during hypoxemia. As ecto-5'-nucleotidase (CD73) is the rate-limiting enzyme for extracellular adenosine generation, it may protect renal IRI through adenosine production. In the current studies, we investigated the effects of CD73 in genetically modified mice. We found that renal IRI caused more serious histological injury, vascular permeability, and lipid peroxidation in CD73(-/-) than that in CD73(+/+) mice. In addition, AMP and free radical concentrations were much higher in CD73(-/-) than that in CD73(+/+) mice. Our data support the fact that CD73 may protect the kidney from IRI through adenosine production and a reduction of free radicals.
© 2011 The Authors. APMIS © 2011 APMIS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22229268     DOI: 10.1111/j.1600-0463.2011.02827.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  11 in total

Review 1.  Purinergic signalling in the kidney in health and disease.

Authors:  Geoffrey Burnstock; Louise C Evans; Matthew A Bailey
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

2.  CD73-generated adenosine is critical for immune regulation during Toxoplasma gondii infection.

Authors:  Deeqa A Mahamed; Leon E Toussaint; Margaret S Bynoe
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

Review 3.  Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.

Authors:  Karen M Dwyer; Bellamkonda K Kishore; Simon C Robson
Journal:  Nat Rev Nephrol       Date:  2020-07-08       Impact factor: 28.314

Review 4.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

Review 5.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 6.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

Review 7.  CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Authors:  Bellamkonda K Kishore; Simon C Robson; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2018-01-13       Impact factor: 3.765

Review 8.  Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.

Authors:  Simone de Leve; Florian Wirsdörfer; Verena Jendrossek
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

9.  Rice Bran Phenolic Compounds Regulate Genes Associated with Antioxidant and Anti-Inflammatory Activity in Human Umbilical Vein Endothelial Cells with Induced Oxidative Stress.

Authors:  Nancy Saji; Nidhish Francis; Christopher L Blanchard; Lachlan J Schwarz; Abishek B Santhakumar
Journal:  Int J Mol Sci       Date:  2019-09-23       Impact factor: 5.923

10.  Host surface ectonucleotidase-CD73 and the opportunistic pathogen, Porphyromonas gingivalis, cross-modulation underlies a new homeostatic mechanism for chronic bacterial survival in human epithelial cells.

Authors:  Jaden S Lee; Nityananda Chowdhury; JoAnn S Roberts; Özlem Yilmaz
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.